Research programme: hydroxysteroid dehydrogenase inhibitors -Pfizer
Latest Information Update: 13 Mar 2008
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 06 Apr 2006 Preclinical trials in Obesity in USA (unspecified route)
- 06 Apr 2006 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)